Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Aeterna Zentaris Inc. today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.

27 Jul 2011

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Roche announced today that the cobas KRAS Mutation Test is now commercially available in Europe for use in colorectal cancer.

22 Jul 2011

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama.

22 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

U.S. physicians to receive nearly $10M from Humana's Provider Quality Rewards Program

Humana Inc. has begun distributing nearly $10 million to physicians across the U.S. who participate in Humana's Provider Quality Rewards Program. Approximately 2,800 physician practices will receive payments of as much as $175,000 in recognition of performance improvements their practices made during 2010 related to improved outcomes for Humana's Medicare members.

21 Jul 2011

French scientists publish paper on guidelines for drinking and relation of alcohol to cancer

A group of French scientists have published a paper in the Canadian Medical Association Journal (CMAJ) on guidelines for drinking and the relation of alcohol to cancer.

21 Jul 2011

Enrollment commences in Exact Sciences' colorectal cancer screening trial

Exact Sciences today announced the initiation of the pivotal trial for the company's multi-marker molecular diagnostic screening test for the early detection of colorectal cancer.

13 Jul 2011

Men more likely to succumb to cancer

According to a new analysis of 36 different types of tumors and blood cancers that affect both sexes, men are more likely than women to get and die of cancer. The report shows that leukemia and cancers of the colon and rectum, pancreas, and liver killed about one and a half to two times as many men as women in the U.S. over a 30-year period. Lung cancer killed nearly two and a half times as many men during that time. According to the American Cancer Society men have about a 1 in 2 chance of developing cancer at some point in their lives, compared with women, who have a 1 in 3 chance.

13 Jul 2011

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine, in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

12 Jul 2011

Blood tests encourage more people to participate in regular screening for colorectal cancer

Epigenomics AG, the cancer molecular diagnostics company, today announced the results of a survey conducted at europacolon's first European CRC Patient Conference, The Power of Patient Voice 2011, showing that patients believe tests using blood samples would encourage more people to participate in regular screening for colorectal cancer.

8 Jul 2011

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Idera Pharmaceuticals today provides an update on the clinical development of IMO-2055 (EMD 1201081), a TLR9 agonist for cancer treatment being developed by Merck KGaA, Darmstadt, Germany, under its collaboration with Idera.

8 Jul 2011

Study finds large state disparities in progress against colorectal cancer mortality rates

Improvements in colorectal cancer mortality rates are concentrated in the northern part of the United States, while southern states continue to fall behind, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Jul 2011

Study finds link between genetic variation and cetuximab rectal cancer therapy

team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery.

7 Jul 2011

Progress in reducing colorectal cancer mortality rates varies across U.S. states

Progress in reducing colorectal cancer (CRC) mortality rates varies significantly across states, with rates in the Northeast showing the most progress and those in the South showing the least progress, according to a new study.

7 Jul 2011

High folate intake linked with reduced risk of colorectal cancer

A new study finds high folate intake is associated with a reduced risk of colorectal cancer, a finding consistent with the findings of most previous epidemiologic studies.

6 Jul 2011

Avastin for breast cancer still covered by Medicare despite FDA indecision

The Medicare will continue to cover Avastin for breast cancer treatment even if U.S. Food and Drug Administration Commissioner Peggy Hamburg decides to withdraw Avastin for such use, according to Don McLeod, a spokesman for the Centers for Medicare and Medicaid. McLeod said, in his statement, “The FDA decision, when it comes, does not affect CMS.”

1 Jul 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years.

29 Jun 2011

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Polymedco, Inc. is pleased to announce the direct availability of the BTA stat® test from our sales force – The BTA stat® test is a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine.

27 Jun 2011

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Roche's cobas KRAS Mutation Test for colorectal cancer now available in Europe

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

U.S. physicians to receive nearly $10M from Humana's Provider Quality Rewards Program

French scientists publish paper on guidelines for drinking and relation of alcohol to cancer

Enrollment commences in Exact Sciences' colorectal cancer screening trial

Men more likely to succumb to cancer

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Blood tests encourage more people to participate in regular screening for colorectal cancer

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Study finds large state disparities in progress against colorectal cancer mortality rates

Study finds link between genetic variation and cetuximab rectal cancer therapy

Progress in reducing colorectal cancer mortality rates varies across U.S. states

High folate intake linked with reduced risk of colorectal cancer

Avastin for breast cancer still covered by Medicare despite FDA indecision

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

DiagnoCure, Signal Genetics enter commercialization collaboration for Previstage GCC Colorectal Cancer Staging Test

Polymedco launches BTA stat test for detection of recurrent bladder cancer

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in